Cushing Syndrome Treatment Market By Disease Type (Endogenous Cushing Syndrome, Exogenous Cushing Syndrome); By Treatment Type (Drug Therapy, Surgery, Radiation Therapy, Supportive Therapy); By Drug Class (Steroidogenesis Inhibitors, Glucocorticoid Receptor Antagonists, Somatostatin Analogs, ACTH Targeted Therapies); By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals and Clinics, Specialty Endocrine Centers, Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Cushing Syndrome Treatment Advances Toward Targeted Cortisol Control and Long-Term Disease Management

The Global Cushing Syndrome Treatment Market was valued at USD 970 million in 2025 and is projected to reach USD 1.63 billion by 2032, growing at a CAGR of 7.85% during 2026–2032, according to Strategic Market Research.

 

Cushing syndrome is a rare endocrine disorder caused by abnormally high levels of cortisol in the body. The treatment market includes cortisol-lowering drugs, cortisol receptor blockers, pituitary-directed therapies, surgery, radiotherapy, diagnostic monitoring, and supportive care. NIDDK estimates endogenous Cushing syndrome affects approximately 40–70 people per million in the U.S., primarily adults aged 30–50 years, with women affected about three times more often than men. In addition, widespread corticosteroid use contributes to cases of exogenous Cushing syndrome, affecting a broader patient population.

 

Globally, endogenous Cushing syndrome affects approximately 57–79 individuals per million, with 1.8–4.5 new cases per million annually. The disease shows a strong female predominance, with women accounting for nearly four times more cases than men, and diagnosis typically occurring around 44 years of age. In the United States, confirmed incidence is estimated at 10–15 new cases per million annually, highlighting the need for improved diagnosis and long-term disease management.

 

The therapeutic landscape is advancing with targeted pharmacological options designed to control cortisol excess and improve patient outcomes. Isturisa (osilodrostat) reduces cortisol production by inhibiting the 11-beta-hydroxylase enzyme and is used when surgery is not possible or unsuccessful. Recorlev (levoketoconazole) provides another cortisol synthesis inhibition approach for persistent disease. Korlym (mifepristone) blocks cortisol receptor activity to manage hyperglycemia and diabetes-related complications, while Signifor (pasireotide) targets pituitary-driven Cushing’s disease when surgery is unsuitable.

 

Overall, the Cushing syndrome treatment market is expanding due to increasing disease recognition, advancements in endocrine diagnostics, rising demand for targeted therapies, and the growing need for effective long-term management of a rare but highly impactful hormonal disorder.

 

Disease Origin, Treatment Pathways, Drug Classes, and Care Channels Define the Market Structure

Segments: By Disease Type

• Endogenous Cushing syndrome led with an 82% share and USD 795 million in 2025 because tumor-related disease frequently requires surgery, branded medicines, biochemical monitoring, and long-term follow-up.

• Exogenous Cushing syndrome held an 18% share and USD 175 million, with commercial activity concentrated in supervised corticosteroid reduction and management of associated complications.

 

Segments: By Treatment Type

• Drug therapy led with a 55% share and USD 534 million as medicines are widely used for nonsurgical, persistent, recurrent, preoperative, and post-radiotherapy disease control.

• Surgery represented a 28% share and USD 272 million, reflecting the first-line position of pituitary tumor resection and adrenalectomy.

• Radiation therapy accounted for a 9% share and USD 87 million and primarily serves patients with persistent or recurrent pituitary-dependent disease.

• Supportive therapy represented an 8% share and USD 77 million through management of metabolic, cardiovascular, skeletal, psychiatric, and postoperative complications.

 

Segments: By Drug Class

• Steroidogenesis inhibitors led with a 45% share and USD 437 million due to their direct cortisol-lowering action and established position in clinical practice.

• Glucocorticoid-receptor antagonists held a 28% share and USD 272 million, particularly serving patients with hypercortisolism-related glucose complications.

• Somatostatin analogs accounted for a 17% share and USD 165 million through pituitary-directed treatment of selected ACTH-dependent cases.

• ACTH-targeted therapies represented a 10% share and USD 97 million and recorded the fastest projected drug-class growth as new upstream treatments advance.

 

Segments: By Distribution Channel

• Specialty pharmacies led with a 42% share and USD 407 million by coordinating access, reimbursement, adherence, and delivery of branded orphan medicines.

• Hospital pharmacies held a 30% share and USD 291 million through treatment initiation, perioperative care, and management of severe hypercortisolism.

• Retail pharmacies accounted for an 18% share and USD 175 million, mainly supplying established oral medicines and supportive therapies.

• Online pharmacies represented a 10% share and USD 97 million and are the fastest-growing channel due to expanding home-delivery and digital refill models.

 

Segments: By End User

• Hospitals and clinics led with a 60% share and USD 582 million because diagnosis, surgery, radiotherapy, medication initiation, and complication management are concentrated in hospital settings.

• Specialty endocrine centers held a 30% share and USD 291 million, supported by referrals for advanced testing, complex treatment selection, and recurrence monitoring.

• Research institutes accounted for a 10% share and USD 97 million through clinical trials, biomarker studies, and development of new endocrine therapies.

 

Segments: By Geography

• North America led with a 45% share and USD 437 million due to its approved therapy portfolio, specialist infrastructure, and established specialty-pharmacy model.

• Europe held a 30% share and USD 291 million, supported by structured endocrine referral networks and access to targeted therapies.

• Asia Pacific accounted for a 17% share and USD 165 million and is the fastest-growing region as diagnostic and specialist treatment capacity improves.

• Latin America represented a 5% share and USD 49 million, with care concentrated in major referral hospitals in Brazil, Mexico, and Argentina.

• The Middle East & Africa held a 3% share and USD 29 million, with advanced treatment concentrated in selected tertiary healthcare systems.

 

Endogenous Disease Burden and Cortisol-Lowering Medicines Anchor Segment Leadership

Endogenous Cushing syndrome was the leading disease-type segment, accounting for approximately 82% of the market and USD 795 million in 2025. Its dominance reflects the substantial treatment expenditure associated with pituitary adenomas, adrenal tumors, and ectopic ACTH-producing tumors. These patients frequently require biochemical testing, imaging, surgery, branded cortisol-lowering medicines, and lifelong recurrence monitoring.

Exogenous Cushing syndrome was the fastest-growing disease-type segment, with a projected CAGR of 8.9% during 2026–2032. Its expansion is associated with the extensive use of corticosteroids for autoimmune, inflammatory, respiratory, and other chronic diseases. Commercial activity mainly involves supervised steroid tapering, adrenal-function assessment, alternative treatment selection, and management of metabolic and skeletal complications.

 

Drug Therapy Expands Across Persistent, Recurrent, and Nonsurgical Disease

Drug therapy was both the leading and fastest-growing treatment segment, representing approximately 55% of the market and USD 534 million in 2025 and expanding at a CAGR of 8.6% through 2032. Medicines are used in patients who cannot undergo surgery, remain hypercortisolemic after surgery, experience recurrence, need preoperative cortisol control, or require temporary control while radiotherapy takes effect. The availability of Isturisa, Recorlev, Korlym, and Signifor has widened the choice of adrenal-directed, receptor-blocking, and pituitary-directed treatments.

 

Steroidogenesis Inhibitors Lead as ACTH-Targeted Therapies Open an Upstream Pathway

Steroidogenesis inhibitors led the drug-class category with approximately 45% share and USD 437 million in 2025. Their dominant position comes from their ability to directly reduce adrenal cortisol production across multiple forms of endogenous Cushing syndrome. Recordati’s Isturisa and Xeris Biopharma’s Recorlev strengthen this segment, while metyrapone and ketoconazole remain established treatment options.

ACTH-targeted therapies were the fastest-growing drug class, with a projected CAGR of 10.1% during 2026–2032. These therapies seek to block ACTH signaling before it stimulates adrenal cortisol production, offering an upstream approach distinct from conventional steroidogenesis inhibition. Development activity includes Crinetics’ investigational atumelnant, an oral ACTH receptor antagonist being studied for ACTH-dependent Cushing syndrome.

 

Specialty Distribution Leads While Digital Fulfilment Improves Treatment Continuity

Specialty pharmacies were the leading distribution channel, capturing approximately 42% of the market and USD 407 million in 2025. Branded orphan therapies commonly require prior authorization, reimbursement assistance, patient onboarding, adherence monitoring, and coordinated delivery. Specialty pharmacies therefore connect manufacturers, endocrinologists, payers, and patients throughout long-term treatment.

Online pharmacies were the fastest-growing distribution channel, with an estimated CAGR of 10.5% through 2032. Electronic prescriptions, remote refill coordination, and home delivery improve continuity for patients receiving chronic oral therapy. Expansion will remain closely connected to verified prescription controls and coordination with specialist endocrinology teams.

 

Hospital-Based Care Leads as Specialty Endocrine Centers Gain Strategic Importance

Hospitals and clinics led the end-user segment with approximately 60% share and USD 582 million in 2025. Their dominance reflects the concentration of biochemical diagnosis, pituitary and adrenal imaging, surgery, radiotherapy, medication initiation, and complication management in hospital-based settings. These facilities also manage patients with severe hypercortisolism and postoperative adrenal insufficiency.

Specialty endocrine centers were the fastest-growing end-user segment, expanding at a projected CAGR of 9.1% during 2026–2032. These centers manage difficult diagnoses, recurrent disease, treatment switching, inferior petrosal sinus sampling, and multidisciplinary surgical assessment. Their specialist expertise also supports the adoption of newer therapies and recruitment into rare-disease clinical trials.

 

North American Therapy Access Contrasts with Faster Asia Pacific Capacity Expansion

North America was the leading regional segment, accounting for approximately 45% of the market and USD 437 million in 2025. The United States benefits from multiple FDA-approved therapies, experienced pituitary centers, advanced diagnostic infrastructure, specialty-pharmacy networks, and established commercialization by Recordati, Corcept Therapeutics, and Xeris Biopharma.

Asia Pacific was the fastest-growing regional segment, with a projected CAGR of 9.5% during 2026–2032. Japan and Australia have established specialist endocrine systems, while China, India, and South Korea are expanding access to biochemical testing, advanced imaging, pituitary surgery, and targeted medicines. Wider diagnosis and treatment availability outside major urban hospitals will determine the region’s long-term commercial development.

 

Recordati Leads Through Complementary Adrenal-Directed and Pituitary-Directed Therapies

The Cushing Syndrome Market is concentrated among a limited number of rare-endocrinology companies competing through treatment efficacy, safety, indication breadth, mechanism of action, specialist access, and patient-support services. Recordati is considered the leading company because it holds the broadest dedicated commercial portfolio covering both cortisol-synthesis inhibition and pituitary-directed treatment.

Recordati

Recordati leads the market through Isturisa (osilodrostat) and Signifor (pasireotide). Isturisa is an oral cortisol-synthesis inhibitor that blocks 11-beta-hydroxylase, an enzyme required for cortisol production. It is indicated in the United States for endogenous hypercortisolemia in adults with Cushing syndrome when surgery is not an option or has not been curative. The FDA’s April 2025 indication expansion widened the product’s eligible population beyond pituitary-origin Cushing disease to additional endogenous causes, strengthening Recordati’s competitive reach.

Signifor gives Recordati a second, differentiated treatment pathway by targeting somatostatin receptors on pituitary tumors to reduce ACTH secretion and downstream cortisol production. The combination of an oral adrenal-directed therapy and a pituitary-directed somatostatin analog enables Recordati to serve different patient profiles across persistent, recurrent, and nonsurgical disease. Its specialist-prescriber relationships, rare-disease commercialization infrastructure, and presence across the United States and Europe further support its leading position.

Other Market Participants

Corcept Therapeutics, Xeris Biopharma, Crinetics Pharmaceuticals, Novartis, Perrigo/HRA Pharma, Esteve, and Teva participate through marketed medicines, generic treatments, or investigational therapies but do not currently match Recordati’s combined portfolio breadth across adrenal-directed and pituitary-directed Cushing syndrome treatment.

 

Precision Endocrine Care, Earlier Diagnosis, and Integrated Monitoring Define Future Commercial Value

The future of the Cushing syndrome treatment market will be driven by the shift toward more effective, personalized, and long-term cortisol management solutions. Significant opportunities exist in patients with persistent or recurring disease after surgery, those who are not surgical candidates, and individuals requiring lifelong medical therapy. Growth is expected from next-generation treatments targeting earlier steps in the cortisol pathway, including ACTH inhibition, improved enzyme blockers, and combination therapies designed to achieve better disease control with fewer side effects.

Beyond drug innovation, improving diagnosis remains a major market opportunity. Many patients remain undiagnosed because Cushing syndrome symptoms often resemble common conditions such as obesity, diabetes, and hypertension. Advanced screening tools, hormone-monitoring technologies, and improved referral pathways could expand patient identification and increase treatment adoption.

The market is also moving toward integrated care models combining medications, digital monitoring, specialty support services, and multidisciplinary endocrine management. Companies that deliver safer therapies, convenient dosing, sustained cortisol control, and improved patient outcomes will gain competitive advantages. Overall, future market growth will depend on addressing unmet patient needs, expanding diagnosis rates, and transforming Cushing syndrome management from reactive treatment into continuous precision endocrine care.

 

Cushing Syndrome Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 970 Million
Revenue Forecast in 2032	USD 1.63 Billion
Overall Growth Rate	CAGR of 7.85% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Disease Type, By Treatment Type, By Drug Class, By Distribution Channel, By End User, By Geography
By Disease Type	Endogenous Cushing Syndrome, Exogenous Cushing Syndrome
By Treatment Type	Drug Therapy, Surgery, Radiation Therapy, Supportive Therapy
By Drug Class	Steroidogenesis Inhibitors, Glucocorticoid-Receptor Antagonists, Somatostatin Analogs, ACTH-Targeted Therapies
By Distribution Channel	Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By End User	Hospitals and Clinics, Specialty Endocrine Centers, Research Institutes
By Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, Japan, Australia, China, India, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE, South Africa
Market Drivers	Increasing disease recognition, advances in endocrine diagnostics, rising demand for targeted cortisol-lowering therapies, development of ACTH-targeted treatments, specialty-pharmacy expansion, and growing need for long-term disease management
Customization Option	Available upon request